Juliana Tong

Ms. Juliana Tong

The University of Auckland
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2021 in Molecules
Verified
Journal Article
Open access
PDF file
JTJuliana Tong
Juliana Tong
Paul William Richard HarrisPaul William Richard Harris
Paul William Richard Harris
MBMargaret Brimble
Margaret Brimble
Iman KavianiniaIman Kavianinia
Iman Kavianinia
The large number of emerging antibody-drug conjugates (ADCs) for cancer therapy has resulted in a significant market ‘boom’, garnering worldwide attention. Despite ADCs presenting huge challenges to researchers, particularly regarding the identification of a suitable combination of antibody, linker, and payload, as of September 2021, 11 ADCs have been granted FDA approval, with eight of these approved since 2017 alone. Optimism for this therapeutic approach is clear, despite the COVID-19 pandemic, 2020 was a landmark year for deals and partnerships in the ADC arena, suggesting that there remains significant interest from Big Pharma. Herein we review the enthusiasm for ADCs by focusing on the features of those approved by the FDA, and offer some thoughts as to where the field is headed.

26 May 2020 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
JTJuliana Tong
Juliana Tong
Iman KavianiniaIman Kavianinia
Iman Kavianinia
SFScott A. Ferguson
Scott A. Ferguson
GCGregory M. Cook
Gregory M. Cook
Paul William Richard HarrisPaul William Richard Harris
Paul William Richard Harris
MBMargaret Brimble
Margaret Brimble
Thiol–ene CLipPA reaction of a vinyl ester and thiolated peptide for generation of an S-lipidated paenipeptin C′ analogue with broad spectrum antibacterial activity.